121 related articles for article (PubMed ID: 3148366)
1. Oral thyrotropin-releasing hormone treatment in inherited ataxias.
Bonuccelli U; Nuti A; Cei G; Rossi G; Grasso L; Martino E; Muratorio A
Clin Neuropharmacol; 1988 Dec; 11(6):520-8. PubMed ID: 3148366
[TBL] [Abstract][Full Text] [Related]
2. [Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects].
Filla A; De Michele G; Di Martino L; Mengano A; Iorio L; Maggio MA; Campanella G
Riv Neurol; 1989; 59(2):83-8. PubMed ID: 2505370
[TBL] [Abstract][Full Text] [Related]
3. Effects of tartrate thyrotropin-releasing hormone treatment on serum thyrotropin, free triiodothyronine, free thyroxine and prolactin levels in patients with spinocerebellar degeneration.
Merola B; Colao A; Di Renzo G; Filla A; Campanella G; Lombardi G
Horm Res; 1992; 38(3-4):160-3. PubMed ID: 1306848
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of TRH-T for spinocerebellar degeneration--the relation between clinical features and effect of TRH therapy].
Waragai M; Ogawara K; Takaya Y; Hayashi M
Rinsho Shinkeigaku; 1997 Jul; 37(7):587-94. PubMed ID: 9396355
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT.
Kimura N; Kumamoto T; Masuda T; Nomura Y; Hanaoka T; Hazama Y; Okazaki T; Arakawa R
J Neurol Sci; 2009 Jun; 281(1-2):93-8. PubMed ID: 19286195
[TBL] [Abstract][Full Text] [Related]
6. [Spinocerebellar degeneration and neuropeptides].
Matsuoka Y; Sakurai N
Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1705-8. PubMed ID: 2516527
[No Abstract] [Full Text] [Related]
7. The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications.
Fröhlich E; Wahl R
Front Neuroendocrinol; 2019 Jan; 52():29-43. PubMed ID: 29935915
[TBL] [Abstract][Full Text] [Related]
8. Plasma thyrotropin-releasing hormone, prolactin, thyrotropin, and thyroxine concentrations following the intravenous or oral administration of thyrotropin-releasing hormone.
Andreassen B; Huth J; Tyson JE
Am J Obstet Gynecol; 1979 Nov; 135(6):737-42. PubMed ID: 115316
[TBL] [Abstract][Full Text] [Related]
9. Treatment of endogenous depressions with thyrotropin-releasing hormone (TRH) under oral administration.
Schmidt J
Acta Psychiatr Scand; 1977 Feb; 55(2):142-6. PubMed ID: 402795
[TBL] [Abstract][Full Text] [Related]
10. Clinical observations on therapeutic applications of thyrotropin-releasing hormone (TRH).
Sakoda M; Mori H; Yamada A; Kusaka T; Tateiwa M
Kobe J Med Sci; 1974 Jun; 20(2):65-81. PubMed ID: 4218287
[No Abstract] [Full Text] [Related]
11. [The effect of the thyrotropin releasing hormone (TRH) on the motor speech disorder in spinocerebellar degeneration].
Nozaki Y; Hashimoto M; Ohnishi A; Murai Y; Ogata H; Makishima K
J UOEH; 1992 Jun; 14(2):173-83. PubMed ID: 1621012
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration.
Shimizu T; Tsutsumi R; Shimizu K; Tominaga N; Nagai M; Ugawa Y; Nishiyama K; Hanajima R
J Neurol Sci; 2020 Aug; 415():116927. PubMed ID: 32474221
[TBL] [Abstract][Full Text] [Related]
13. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
14. Clinical manifestations and thyrotropin releasing hormone therapy in cerebellar degenerations.
Wang HC; Chiu HC
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Mar; 47(3):161-8. PubMed ID: 1848143
[TBL] [Abstract][Full Text] [Related]
15. Lack of evidence for pituitary thyrotroph down-regulation after 1 week of oral thyrotrophin-releasing hormone and metoclopramide under conditions of constant peripheral thyroid hormone levels.
Grebe SK; Delahunt JW; Feek CM; Purdie G; Porter DJ
Eur J Endocrinol; 1995 Mar; 132(3):331-7. PubMed ID: 7889183
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin-releasing hormone (TRH) inchronic schizophrenia. A controlled study.
Lindström LH; Gunne LM; Ost LG; Persson E
Acta Psychiatr Scand; 1977 Jan; 55(1):74-80. PubMed ID: 402794
[TBL] [Abstract][Full Text] [Related]
17. Spinocerebellar degeneration and neuropeptides.
Matsuoka Y; Sakurai N
Jpn J Med; 1989; 28(6):791-3. PubMed ID: 2517445
[No Abstract] [Full Text] [Related]
18. Acute and chronic effects of thyrotropin-releasing hormone (TRH) on stabilogram in spinocerebellar degenerations.
Yoshida M; Nakanishi T; Komatsu Y
Tohoku J Exp Med; 1986 Mar; 148(3):327-31. PubMed ID: 3085285
[TBL] [Abstract][Full Text] [Related]
19. Synthetic thyroid releasing hormone (TRH) administered orally to chronic schizophrenic patients.
Clark ML; Paredes A; Costiloe JP; Wood F
Psychopharmacol Commun; 1975; 1(2):191-200. PubMed ID: 817373
[TBL] [Abstract][Full Text] [Related]
20. Effect of thyrotropin-releasing hormone (TRH) on cerebral blood flow in spinocerebellar degeneration and cerebrovascular disease.
Izumi Y; Fukuuchi Y; Ishihara N; Imai A; Komatsumoto S
Tokai J Exp Clin Med; 1995 Dec; 20(4-6):203-8. PubMed ID: 8956461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
